Dr. Anas Younes,MD

Chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center ,Professor, Weill-Cornell Medical College, New York
Dr. Anas Younes is chief of Memorial Sloan Kettering’s Lymphoma Service, Division of Hematologic Oncology, where he is responsible for continuing to accelerate the translation of scientific discoveries into novel treatment strategies to improve the cure rate and survival of patients with Hodgkin (HL) and non-Hodgkin lymphoma (NHL). His interests include HL, NHL, developing novel targeted therapies for lymphoma, identification of biomarkers for treatment, and participation in clinical trials. He led the trials that resulted in the FDA approval of brentuximab vedotin and nivolumab for the treatment of patients with relapsed Hodgkin lymphoma. Dr. Younes has published more than 250 papers, and serves on the Scientific Advisory Board of the Lymphoma Research Foundation. He is a past member of the National Cancer Institute Lymphoma Steering Committee. He has served as the principal investigator of more than 60 clinical trials and has led the National Cancer Institute-funded SPORE (Specialized Programs of Research Excellence) in lymphoma both at M.D. Anderson Cancer Center, and most recently at MSKCC. He is also the principal investigator of a SCOR grant supported by the Leukaemia and Lymphoma Society.


Dr. Pamela Muster 

Dr. Pamela Munster is an oncologist in San Francisco, California and is affiliated with multiple hospitals in the area, including UCSF Medical Center and Zuckerberg San Francisco General Hospital and Trauma Center. She received her medical degree from University of Bern Faculty of Medicine and has been in practice for more than 20 years. She is one of 76 doctors at UCSF Medical Center and one of 31 at Zuckerberg San Francisco General Hospital and Trauma Centerwho specialize in Oncology.


Jun Guo, MD, PhD

Dept. Melanoma & Renal Cancer, Peking University cancer Hospital & Institute, Beijing, China

Jun Guo MD. PhD. is a professor and the medical director of the Department of Melanoma and Renal Cancer (which he helped to establish) in Peking University Cancer Hospital & Institute. Dr. Guo earned his medical degree and a master’s degree from the Fourth Military Medical University, Xi’an (China), and a PhD from the Second Military Medical University, Shanghai (China). He is a leading researcher in the areas of melanoma and renal cancer in China.

Dr. Guo holds multiple positions, such as the chair of Asian melanoma group, Deputy Secretary-General of Chinese Society of Clinical Oncology (CSCO), president of Melanoma Branch of CSCO, member of Global Melanoma Task Force (GMTF). He is the writing panel chair of “Chinese Guidelines on the Diagnosis and Treatment of Melanoma” and “Chinese Guidelines on the Diagnosis and Treatment of Kidney Cancer”.

Dr. Guo established the first melanoma center in China; he has made pioneering contributions to epidemiology, genetics diagnosis and treatments for Chinese melanoma and renal cancer. Prof. Guo led a domestic team from 24 cancer centers of 13 provinces, which is aimed to conduct multi-center clinical researches. He also established a collaborate platform for melanoma translational research. Prof. Guo leads 15 international multi-center clinical researches and more than 20 domestic multi-center clinical researches. Several researches have been adopted by domestic guidelines and “NCCN guidelines for melanoma, head & neck cancer and renal cancer”.

Dr. Guo has published several research papers in peer-reviewed journals. He published more than 30 academic papers on the most influential cancer research journals in the world (J Clin Oncol, Clin Cancer Res, Eur J Cancer, Blood, Gene Ther, Int J Cancer, etc.).The highest citation frequency was 369. He also leads a number of state and ministry grants, including grants supported by The National Basic Research Program of China, Natural Science Foundation of China. Prof. Guo also achieved several Scientific Technology Advance Awards from Beijing City, China Anticancer Association, and Chinese Medical Association.